Risk of serious and fatal adverse events with sorafenib use in patients with solid cancers

Bookmark and Share
Published: 12 Oct 2016
Views: 2332
Rating:
Save
Dr Bishal Gyawali - Nagoya University, Nagoya, Japan

Dr Gyawali meets with ecancertv at ESMO 2016 to discuss the safety profile of sorafenib, with a 27% increase in the risk of grade 4 and 5 adverse events compared to standard care.

He describes the context of the results from this meta-analysis, considering the balancing of risk and outcome for patients, and the impact of treatment-related hospitalisation on quality of life.

Dr Gyawali spoke further with ecancer about his upcoming publication in ecancers' medical journal, coming soon, and contributes a regular blog with his views on recent research.